Catherine Scholz

1.2k total citations
25 papers, 665 citations indexed

About

Catherine Scholz is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Catherine Scholz has authored 25 papers receiving a total of 665 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Catherine Scholz's work include Advanced Breast Cancer Therapies (5 papers), Inflammatory Bowel Disease (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Catherine Scholz is often cited by papers focused on Advanced Breast Cancer Therapies (5 papers), Inflammatory Bowel Disease (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Catherine Scholz collaborates with scholars based in United States, Spain and South Korea. Catherine Scholz's co-authors include Irving H. Fox, Asit Parikh, Timothy Leach, Brian G. Feagan, Serap Sankoh, Diane R. Mould, Tim Wyant, Terry Ponich, Antonio Gualberto and Alan B. Sandler and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Catherine Scholz

23 papers receiving 644 citations

Peers

Catherine Scholz
Fumitaka Numa Japan
Friedrich Schuening United States
Ken Kuramoto Japan
Yih‐Lin Chung Taiwan
Y.F. Wong Hong Kong
Katharina Balschun Germany
Axel Denz Germany
Jürgen Enczmann Germany
K. Witter Germany
CJH van de Velde Netherlands
Fumitaka Numa Japan
Catherine Scholz
Citations per year, relative to Catherine Scholz Catherine Scholz (= 1×) peers Fumitaka Numa

Countries citing papers authored by Catherine Scholz

Since Specialization
Citations

This map shows the geographic impact of Catherine Scholz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine Scholz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine Scholz more than expected).

Fields of papers citing papers by Catherine Scholz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine Scholz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine Scholz. The network helps show where Catherine Scholz may publish in the future.

Co-authorship network of co-authors of Catherine Scholz

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine Scholz. A scholar is included among the top collaborators of Catherine Scholz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine Scholz. Catherine Scholz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lang, Hauke, Beate K. Straub, Tobias Huber, et al.. (2025). Vascular resection and reconstruction in surgery for advanced intrahepatic cholangiocarcinoma – single center experience with 59 vascular resections. European Journal of Surgical Oncology. 51(9). 110193–110193.
2.
Johnston, Stephen, Timothy Pluard, Judy S. Wang, et al.. (2021). Phase 1b study of H3B-6545 in combination with palbociclib in women with metastatic estrogen receptor–positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative breast cancer.. Journal of Clinical Oncology. 39(15_suppl). e13025–e13025. 9 indexed citations
3.
Lee, Hye Won, K. Jason, Antonio Gualberto, et al.. (2020). A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring HRAS Mutations. Clinical Cancer Research. 26(19). 5113–5119. 36 indexed citations
4.
Guenette, Jeffrey P., Nicole G. Chau, Cyrus Sayehli, et al.. (2020). Tipifarnib in recurrent, metastatic HRAS‐mutant salivary gland cancer. Cancer. 126(17). 3972–3981. 37 indexed citations
5.
Mondéjar, R., Nerea Martı́nez, Cristina Pérez, et al.. (2020). Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphoma. Scientific Reports. 10(1). 6721–6721. 10 indexed citations
6.
7.
Lee, Jiyun, Hana Kim, Antonio Gualberto, Catherine Scholz, & Se Hoon Park. (2020). Tipifarnib, a farnesyltransferase inhibitor, for metastatic urothelial carcinoma harboring HRAS mutations.. Journal of Clinical Oncology. 38(15_suppl). 5086–5086. 1 indexed citations
8.
Gualberto, Antonio, Catherine Scholz, & Eric Van Cutsem. (2019). Patient reported abdominal pain as a surrogate of the clinical benefit of tipifarnib in pancreatic cancer patients.. Journal of Clinical Oncology. 37(4_suppl). 275–275. 2 indexed citations
9.
Kessler, Linda, Catherine Scholz, Antonio Gualberto, Yi Liu, & Francis Burrows. (2018). Abstract 4917: Tipifarnib is highly active in HRAS mutant lung squamous carcinoma tumor models. Cancer Research. 78(13_Supplement). 4917–4917. 1 indexed citations
10.
Witzig, Thomas E., Lubomir Sokol, Eric D. Jacobsen, et al.. (2018). Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study. Blood. 132(Supplement 1). 2937–2937. 2 indexed citations
11.
Ho, Alan L., Nicole G. Chau, Deborah J. Wong, et al.. (2018). Abstract LB-A10: Preliminary results from a phase 2 proof of concept trial of tipifarnib in tumors with HRAS mutations. Molecular Cancer Therapeutics. 17(1_Supplement). LB–A10. 3 indexed citations
12.
Ho, Alan L., Nicole G. Chau, Irene García, et al.. (2018). Preliminary Results From a Phase 2 Trial of Tipifarnib in HRAS-Mutant Head and Neck Squamous Cell Carcinomas. International Journal of Radiation Oncology*Biology*Physics. 100(5). 1367–1367. 6 indexed citations
13.
Gualberto, Antonio, Catherine Scholz, Matthew R. Janes, Linda Kessler, & Azra Raza. (2017). The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Blood. 130. 3957. 4 indexed citations
14.
Ho, Alan L., Nicole G. Chau, Deborah Jean Lee Wong, et al.. (2017). An open-label, phase II study of tipifarnib for the treatment of HRAS mutant solid tumors, including squamous cell carcinomas of the head and neck.. Journal of Clinical Oncology. 35(15_suppl). TPS2618–TPS2618. 5 indexed citations
15.
Witzig, Thomas E., Lubomir Sokol, Eric D. Jacobsen, et al.. (2017). PRELIMINARY RESULTS FROM AN OPEN‐LABEL, PHASE II STUDY OF TIPIFARNIB IN RELAPSED OR REFRACTORY PERIPHERAL T‐CELL LYMPHOMA. Hematological Oncology. 35(S2). 251–252. 4 indexed citations
16.
Rosario, Maria, Timothy Wyant, Timothy Leach, et al.. (2016). Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers. Clinical Drug Investigation. 36(11). 913–923. 38 indexed citations
17.
Parikh, Asit, Irving H. Fox, Timothy Leach, et al.. (2013). Long-term Clinical Experience with Vedolizumab in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 19(8). 1691–1699. 70 indexed citations
18.
Parikh, Asit, Timothy Leach, Tim Wyant, et al.. (2011). Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging Study. Inflammatory Bowel Diseases. 18(8). 1470–1479. 182 indexed citations
19.
Xiong, Henry Q., Roy S. Herbst, Silvana C. Faria, et al.. (2004). A phase I surrogate endpoint study of SU6668 in patients with solid tumors. Investigational New Drugs. 22(4). 459–466. 67 indexed citations
20.
Scholz, Catherine, et al.. (1970). Play a part. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fumitaka Numa Breakdown of academic impact, for papers by Friedrich Schuening Breakdown of academic impact, for papers by Ken Kuramoto Breakdown of academic impact, for papers by Yih‐Lin Chung Breakdown of academic impact, for papers by Y.F. Wong Breakdown of academic impact, for papers by Katharina Balschun Breakdown of academic impact, for papers by Axel Denz Breakdown of academic impact, for papers by Jürgen Enczmann Breakdown of academic impact, for papers by K. Witter Breakdown of academic impact, for papers by CJH van de Velde
Rankless by CCL
2026